Key takeaways SSRIs have the only regulator-audited evidence base of the three. An FDA analysis of individual patient data from 232 trials (Stone et al., BMJ 2022) found that about 15% of participants get a large benefit beyond placebo, and the benefit grows with severity. Published trials overstated the effect by about a third (Turner … Read more
Key takeaways Short-term depression evidence: the Cochrane review included 29 trials and 5,489 patients. Selected extracts improved response versus placebo; comparator findings varied. Fewer withdrawals due to adverse effects versus SSRIs do not establish fewer harms in every category. The review authors disclosed past Schwabe research, speaking or travel support. Evidence is insufficient for severe … Read more
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
